Table 1 Demography and clinical characteristics of total cohort and AIT subgroups
Total cohort | Pollen SCIT | Pollen SLIT | HDM SLIT | P-value | |
|---|---|---|---|---|---|
Number of patients | 249 | 113 (45%) | 42 (17%) | 94 (38%) | |
Patients withdrawn | 49 (20%) | 15 (13%) | 8 (19%) | 26 (28%) | 0.03 |
Age (years) at which patients started treatment Median (IQR) | 13 (10–15) | 15 (12–15) | 11 (9–14) | 12 (10–15) | < 0.001 |
Gender | |||||
Male | 163 (65%) | 77 (68%) | 30 (71%) | 56 (60%) | 0.3 |
Female | 85 (35%) | 36 (32%) | 12 (29%) | 38 (40%) | |
Ethnicity | |||||
White European | 157 (63%) | 84 (74%) | 35 (83%) | 38 (40%) | < 0.001 |
Other | 92 (37%) | 29 (26%) | 7 (17%) | 56 (60%) | |
AR symptoms | |||||
Eyes only | 14 (6%) | 4 (4%) | 7 (17%) | 3 (3%) | 0.01b |
Nose only | 23 (9%) | 7 (6%) | 5 (12%) | 11 (12%) | |
Eyes + nose | 212 (85%) | 102 (90%) | 30 (71%) | 80 (85%) | |
Allergen sensitisationa | |||||
Grass pollen | 29 (12%) | 17 (16%) | 11 (27%) | 1 (1%) | < 0.001b |
Tree pollen | 4 (2%) | 3 (3%) | 1 (3%) | 0 | |
Grass & tree | 34 (14%) | 27 (26%) | 6 (15%) | 1 (1%) | |
HDM | 23 (10%) | 1 (1%) | 0 | 22(24%) | |
HDM & grass | 57 (24%) | 13 (13%) | 13 (31%) | 31 (33%) | |
HDM & tree | 4 (2%) | 0 | 0 | 4 (4%) | |
HDM, grass & tree | 87 (36%) | 43 (41%) | 10 (24%) | 34 (37%) | |
Mono-sensitised to AIT | |||||
Yes | 98 (40%) | 56 (50%) | 19 (45%) | 23 (25%) | < 0.001 |
No | 151 (60%) | 57 (50%) | 23 (55%) | 71 (75%) | |
Medication | |||||
Oral antihistamines | 5 (2%) | 2 (2%) | 1 (2%) | 2 (2%) | 0.8b |
OA + adjunct | 224 (90%) | 99 (88%) | 39 (93%) | 86 (92%) | |
Systemics | 20 (8%) | 12 (10%) | 2 (5%) | 6 (6%) | |
Other atopic disease | |||||
Asthma | 101 (41%) | 51 (45%) | 13 (31%) | 37 (39%) | 0.5 |
Eczema | 21 (8%) | 10 (9%) | 2 (5%) | 9 (10%) | |
Asthma + Eczema | 73 (29%) | 31 (27%) | 6 (14%) | 36 (38%) | |
Baseline RQLQ Median (IQR) | 65 (38–89) | 77 (42–98) | 74 (56–105) | 57 (28–80) | < 0.01 |
Baseline VAS Median (IQR) | 6 (4–8) | 7 (5–8) | 8 (7–9) | 6 (3–7) | < 0.001 |